

- production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
 5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
 6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
 7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship..
 8. Describe the acquisition of new customers or loss of customers.
 9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
 10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
 11. Report on any labour disputes and resolutions of those disputes if applicable.
 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
 14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.
16. Provide details of any changes in directors, officers or committee members.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The company was under a Management Cease Trade Order due to late filing of the Company's audited Financial Statements and Management and Discussion and Analysis. The Audited Financials and the Management Discussion and Analysis were filed with the Alberta Securities Commission and the British Columbia Securities Commission. The Management Cease Trade Order has now been lifted.

On the 22nd of May, Immunall Science Inc. announced that it signed an exclusive distributorship agreement with Infinity Science Corporation ("Infinity") of Canada. The agreement provides Infinity with the exclusive rights to market Immunall's patented immune enhancing product ginsē™ throughout Canada.

Dan Robertson was hired as "Operations Manager" June 2, 2008 for Immunall Science Inc.

On the 21st of July, Immunall Science Inc. announced that it signed an exclusive distributorship agreement with Cold and Flu Response LLC of Boulder Colorado. The agreement provides Cold and Flu Response with exclusive rights to market Immunall's patented immune enhancing product ginsē™ throughout the U.S.

Immunall Science Inc announced in September that one of it's Directors, Mr. Larry Shaben had passed away.

Immunall Science Inc. held it's annual General Meeting September 16th, 2008. All resolutions brought forth were passed including the election of new Director, Mr Craig McLennan.

The Company announced on July 21, 2008 that it has signed an exclusive distributorship agreement with Cold and Flu LLC. of Boulder Colorado, USA. Unfortunately, due to the current financial situation in the USA, Cold and Flu LLC has been unable to secure the necessary funds to finance their product launch and as a consequence the project has been deferred.

It was announced through a press release on December 18th, 2008. That Immunall Science Inc. signed an exclusive distributorship agreement with 7060173 Canada Ltd. The agreement provides 7060173 Canada Ltd. to market Immunall's patent immune enhancing product ginsē™ throughout Serbia, Croatia, Montenegro, Bosnia, Herzegovina and Macedonia.

The Audited Annual Financials and Management Discussion and Analysis were filed with the appropriate Provincial Securities Commissions and posted on SEDAR and SEDI on the 30th of April, 2009.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNQ that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNQ Requirements (as defined in CNQ Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 3rd, 2009.

M. Frank Phillet
Name of Director or Senior
Officer

" M. Frank Phillet"
Signature
Chief Operating Officer
Official Capacity

Issuer Details Name of Issuer Immunall Science Inc.	For Month End June	Date of Report YY/MM/D 09/07/03
Issuer Address 10979,127st		
City/Province/Postal Code Edmonton, Alberta, T5M-0T1	Issuer Fax No. (780)421-9262	Issuer Telephone No. (780)451-7952
Contact Name Frank Phillet	Contact Position COO	Contact Telephone No. (780)452-4229
Contact Email Address info@ginse.ca	Web Site Address www.ginse.ca	